FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2005768504> ?p ?o ?g. }

• W2005768504 endingPage "693" @default.
• W2005768504 startingPage "686" @default.
• W2005768504 abstract "Clinical & Experimental AllergyVolume 31, Issue 5 p. 686-693 Management of systemic lupus erythematosus (SLE) S. J. Morton, S. J. Morton Clinical Immunology Unit, University Hospital, Queens Medical Centre, Nottingham, UKSearch for more papers by this authorR. J. Powell, R. J. Powell Clinical Immunology Unit, University Hospital, Queens Medical Centre, Nottingham, UKSearch for more papers by this author S. J. Morton, S. J. Morton Clinical Immunology Unit, University Hospital, Queens Medical Centre, Nottingham, UKSearch for more papers by this authorR. J. Powell, R. J. Powell Clinical Immunology Unit, University Hospital, Queens Medical Centre, Nottingham, UKSearch for more papers by this author First published: 12 January 2002 https://doi.org/10.1046/j.1365-2222.2001.01123.xCitations: 6 Dr Richard Powell, Clinical Immunology Unit, University Hospital, Queens Medical Centre, Nottingham NG7 2UH, UK. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Mongey A & Hess EV. Antinuclear antibodies and disease specificity. Adv Intern Med 1991; 36: 151–69. 2 Tan EM, Cohen ES, Fries JF et al. Special article: the 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–7. 3 Petri M & Robinson C. Oral contraceptives and systemic lupus erythematosus. Arthritis Rheum 1997; 40: 797–803. 4 Arden NK, Lloyd ME, Spector TD, Hughes GRV. Safety of hormone replacement therapy (HRT) in systemic lupus erythematosus (SLE). Lupus 1994; 3: 11–3. 5 Quisimorio FP. Systemic corticosteroid therapy in systemic lupus erythematosus. In: DJ Wallace, BH Hahn, eds. Dubois' lupus erythematosus. Baltimore: Williams & Wilkins, 1997: 1141–62. 6 Denz H, Fuchs D, Hausen A et al. Value of urinary neopterin in the differential diagnosis of bacterial and viral infections. Klinische Wochenschrift 1990; 68: 218–22. 7 Farhey Y & Hess EV. Accelerated atherosclerosis and coronary disease in SLE. Lupus 1997; 6: 572–7. 8 Wallace DJ. Antimalarial therapies. In: DJ Wallace, BH Hahn, eds. Dubois' lupus erythematosus. Baltimore: Williams & Wilkins, 1997: 1117–39. 9 Petri M. Editorial: Hydroxychloroquine: past, present, future. Lupus 1997; 7: 65–7. 10 Wallace DJ. Toxic effects of Chloroquine and Hydroxychloroquine (Table 60.5). In: DJ Wallace, BH Hahn, eds. Dubois' lupus erythematosus. Baltimore: Williams & Wilkins, 1997: 1124. 11 Blyth C & Lane C. Hydroxychloroquine retinopathy: is screening necessary? BMJ 1998; 316: 716–7. 12 Barba-Rubio J & Franco-Gonzales F. Lupus eritimatoso fijo (su tratamiento con talidomida). Biomed Pharmacother 1990; 44: 199–204. 13 Naafs B, Bakkers EJM, Flintermann J, Faber WR. Thalidomide treatment of subacute cutaneous lupus erythematosus. Br J Dermatol 1982; 107: 83–6. 14 Knop J, Happle R, Vakilzadech F, Macher E. Treatment of lupus erythematosus profundus with thalidomide. Arch Dermatol Res 1981; 270: 229. 15 Atra E & Sato EJ. Treatment of cutaneous lesions of systemic lupus erythematosus with thalidomide. Clin Exp Rheumatol 1993; 11: 487–93. 16 Powell RJ & Gardner-Medwin JMM. Guideline for the clinical use and dispensing of thalidomide. Postgrad Med J 1994; 70: 901–4. 17 Fullerton PM & Kremer M. Neuropathy after intake of thalidomide (Distaval). BMJ 1961; 2: 855–8. 18 Dayan M, Segal R, Mozes E. Cytokine manipulation by methotrexate treatment in murine experimental systemic lupus erythematosus. J Rheumatol 1997; 24: 1075–82. 19 Walz Leblanc BAE, Dagenais P, Urowitz MB, Gladman DD. Methotrexate in systemic lupus erythematosus. J Rheumatol 1994; 21: 836–8. 20 Wise CM, Vuyyura S, Roberts WN. Methotrexate in nonrenal lupus and undifferentiated connective tissue disease—a review of 36 patients. J Rheumatol 1996; 23: 1005–10. 21 Gansauge S, Breitbart A, Rinaldi N, Schwarz-Eywill M. Methotrexate in patients with moderate systemic lupus erythematosus (exclusion of renal and central nervous system disease). Ann Rheum Dis 1997; 56: 382–5. 22 Kipen Y, Littlejohn GO, Morand EF. Methotrexate use in systemic lupus erythematosus. Lupus 1997; 6: 1997. 23 British Medical Association and the Royal Pharmaceutical Society of Great Britain. Methotrexate—cautions; side effects. In: British national formulary. Oxon, UK: The Pharmaceutical Press, 1997: 484. 24 Gardner-Medwin J & Powell RJ. Maintenance azathioprine reduces the incidence of relapse in systemic lupus erythematosus (SLE). Arthritis Rheum 1996; 39 (Abstr.): S255. 25 McCune WJ. Cytotoxic drugs. In: DJ Wallace, BH Hahn, eds. Dubois' lupus erythematosus. Baltimore: Williams & Wilkins, 1997: 1173(Table). 26 Ginzler E, Diamond H, Guttadauria M, Kaplan D. Prednisolone and azathioprine compared to prednisone plus low dose azathioprine and cyclophosphamide in the treatment of diffuse lupus nephritis. Arthritis Rheum 1976; 19: 693–9. 27 British Medical Association and the Royal Pharmaceutical Society of Great Britain. Azathioprine: side effects. In: British national formulary. Oxon, UK: The Pharmaceutical Press, 1997: 372. 28 Weinshilboum RM & Sladek SL. Mercaptopurine pharmacogenetics: monogenetic inheritance of erythrocyte thiopurine methyltransferase deficiency. Am J Hum Genet 1980; 32: 651. 29 British Medical Association and the Royal Pharmaceutical Society of Great Britain. Azathioprine: cautions. In: British national formulary. Oxon, UK: The Pharmaceutical Press, 1997: 372. 30 Favre H, Miescher PA, Huang YP, Chatelanat F, Mihatsch MJ. Cyclosporin in the treatment of lupus nephritis. Am J Nephrol 1989; 9: 57–60. 31 Feutren G, Querin S, Tron F et al. The effects of cyclosporin in patients with systemic lupus. Transplant Proc 1986; 18: 643–4. 32 Balletta M, Sabella D, Magri P et al. Cyclosporin plus steroids versus steroids alone in the treatment of lupus nephritis. Contrib Nephrol 1992; 19: 129–30. 33 Radhakrishnan J, Valeri A, Kunis C, Appel GB. Use of cyclosporin in lupus nephritis. Contrib Nephrol 1995; 114: 59–72. 34 Manger K, Kalden JR, Manger B. Cyclosporin A in the treatment of systemic lupus erythematosus: results of an open clinical study. Br J Rheumatol 1996; 35: 669–75. 35 Caccavo D, Lagana B, Mitterhofer AP et al. Long-term treatment of systemic lupus erythematosus with cyclosporin A. Arthritis Rheum 1997; 40: 27–35. 36 Morton SJ & Powell RJ. An audit of cyclosporin for SLE and related overlap syndromes: limitations of use. Ann Rheum Dis 2000; 59: 487–9. 37 Miescher PA, Favre H, Mihatsch MJ, Chatelanat F, Huang YP, Zubler R. The place of cyclosporine A in the treatment of connective tissue diseases. Transplant Proc 1988; 20 (Suppl.4): 224–37. 38 Takabayashi K, Koite T, Kurasawa K et al. Effect of FK-506, a novel immunosuppressive drug on murine systemic lupus erythematosus. Clin Immol Immunopathol 1989; 51: 110–7. 39 Duddridge M & Powell RJ. The treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus—a report of three cases. Ann Rheum Dis 1997; 56: 690–2. 40 McCune WJ. Cytotoxic drugs. In: DJ Wallace, BH Hahn, eds. Dubois' lupus erythematosus. Baltimore: Williams and Wilkins, 1997: 1164–70. 41 Stillwell TJ & Benson RC Jr. Cyclophosphamide-induced hemorrhagic cystitis. A review of 100 patients. Cancer 1988; 61: 451–7. 42 Cannon GW, Jackson CG, Saumualson CO, Ward JR, Williams HJ, Clegg DO. Chlorambucil therapy in rheumatoid arthritis: clinical experience in 28 patients and literature review. Semin Arthritis Rheum 1985; 15: 106–18. 43 Patapanian J, Graham S, Sambrook PN et al. The oncogenicity of chlorambucil in rheumatoid arthritis. Br J Rheumatol 1988; 27: 44–7. 44 Kitchin JES, Pomeranz MK, Pak G, Washenik K, Shupack JL. Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses. J Am Acad Derm 1997; 37: 445–9. 45 Zimmer-Moisberger B, Knauf W, Thiel E. Mycophenolate mofetil for severe autoimmune haemolytic anaemia. Lancet 1997; 350: 1003–4. 46 Enk AH & Knop J. Treatment of pemphigus vulgaris with mycophenolate mofetil. Lancet 1997; 350: 494. 47 Bohm M, Beissert S, Schwarz T, Metze D, Luger T. Bullous pemphigoid treated with mycophenolate mofetil. Lancet 1997; 349: 541.DOI: 10.1016/s0140-6736(97)80092-x 48 Nowack R, Birck R, Van der Woude FJ. Mycophenolate mofetil for systemic vasculitis and IgA nephropathy. Lancet 1997; 349: 774. 49 Cross J & Jayne D. Mycophenolate mofetil in lupus nephritis. Lupus 2000; 9: 647–50. 50 Ostraat O, Qi Z, Olausson M, Gannedahl G, Tufvenson G, Ekberg H. Additive immunosuppressive effect of combined mycophenolate mofetil and cyclosporin A in experimental rat cardiac transplantation. Transport Proc 1995; 27:3540. 51 British Medical Association and the Royal Pharmaceutical Society of Great Britain. Mycophenolate mofetil: side effects . In: British national formulary. Oxon, UK: The Pharmaceutical Press, 1997: 372. 52 Kontogiannis V, Lanyon PC, Powell RJ. Cladribine in the treatment of systemic lupus erythematosus nephritis [letter]. Ann Rheum Dis 1999; 58: 653. 53 Davis CJ, Austin H, Boumpas D et al. A pilot study of 2-chloro-2′deoxyadenosine in the treatment of systemic lupus erythematosus-associated glomerulonephritis. Arthritis Rheum 1998; 41: 335–43. 54 Kambic H, Hyslop L, Nose Y. Topics in plasmapharesis: a bibliography of therapeutic applications and new techniques. Cleveland: ISAO Press, 1985. 55 Schroeder JO, Zeuner RA, Euler HH, Loffler H. High dose intravenous immunoglobulins in systemic lupus erythematosus: clinical and serological results of a pilot study. J Rheumatol 1996; 23: 71–5. 56 Winder A, Molad Y, Ostfield I, Kenet G, Pinkhas J, Sidi Y. Treatment of systemic lupus erythematosus by prolonged administration of high dose intravenous immunoglobulin: report of 2 cases. J Rheumatol 1993; 20: 495–8. 57 Heyneman CA, Gudger CA, Beckwith JV. Intravenous immunoglobulins for inducing remissions in systemic lupus erythematosus. Ann Pharmacother 1997; 31: 242–4. 58 Holbrook MR & Powell RJ. Is there a future for extracorporeal photochemotherapy in the treatment of the rheumatologic diseases? Ann Rheum Dis 1997; 56: 339–40. 59 Marmont AM, Van Lint MT, Gualandi F, Bacigalupo A. Autologous marrow stem cell transplantation for severe systemic lupus erythematosus of long duration. Lupus 1997; 6: 545–8. 60 Snowden JA, Patton WN, O'Donnell JL, Hannah EE, Hart DNJ. Prolonged remission of longstanding systemic lupus erythematosus after autologous bone marrow transplant for non-Hodgkin's lymphoma. Bone Marrow Transplant 1997; 19: 1247–50. 61 Meloni G, Capria S, Vignetti M, Mandelli F, Modena V. Blast crisis of chronic myelogenous leukaemia in long-lasting systemic lupus erythematosus: regression of both diseases after autologous bone marrow transplantation. Blood 1997; 89: 4659. 62 Euler HH, Marmont AM, Bacigalupo A et al. Early recurrence or persistence of autoimmune diseases after unmanipulated autologous stem cell transplantation. Blood 1996; 88: 3621–5. 63 Burt RK, Traynor A, Ramsay-Goldman R. Haematopoietic stem-cell transplantation for systemic lupus erythematosus. NEJM 1997; 337: 1777–8. 64 Hahn BH. The potential role of autologous stem cell transplantation in patients with systemic lupus erythematosus. J Rheumatol 1997; 24 (Suppl. 48): 89–93. 65 Petri M. Clinical and management aspects of the antiphospholipid syndrome. In: DJ Wallace, BH Hahn, eds. Dubois' lupus erythematosus. Baltimore: Williams & Wilkins, 1997: 1077(Table). 66 Hughes GRV. The antiphospholipid syndrome: ten years on. Lancet 1993; 342: 341–4. 67 Lockshin MD. Which patients with antiphospholipid antibodies should be treated and how? Rheum Dis Clin North Am 1993; 19: 235–47. 68 Rosove MH & Brewer PMC. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992; 117: 303–8. 69 Santiago M. Antiphospholipid antibodies in autoimmune and infectious diseases. Participation of beta-2-glycoprotein 1. Revista Brasileira Rheumatologia 1997; 37: 282–6. 70 Petri M & Allbritton J. Fetal outcome of lupus pregnancy: a retrospective case-control study of the Hopkin's lupus cohort. J Rheumatol 1993; 20: 650–7. 71 Kitridou RC. The mother in systemic lupus erythematosus. In: DJ Wallace, BH Hahn, eds. Dubois' lupus erythematosus. Baltimore: Williams & Wilkins, 1997: 983–91. Citing Literature Volume31, Issue5May 2001Pages 686-693 ReferencesRelatedInformation" @default.
• W2005768504 created "2016-06-24" @default.
• W2005768504 creator A5038000493 @default.
• W2005768504 creator A5069101548 @default.
• W2005768504 date "2001-05-01" @default.
• W2005768504 modified "2023-09-25" @default.
• W2005768504 title "Management of systemic lupus erythematosus (SLE)" @default.
• W2005768504 cites W148001558 @default.
• W2005768504 cites W1967543427 @default.
• W2005768504 cites W1980498033 @default.
• W2005768504 cites W1980784832 @default.
• W2005768504 cites W1990006755 @default.
• W2005768504 cites W1990255427 @default.
• W2005768504 cites W2001678873 @default.
• W2005768504 cites W2002207507 @default.
• W2005768504 cites W2011880796 @default.
• W2005768504 cites W2013465107 @default.
• W2005768504 cites W2014596999 @default.
• W2005768504 cites W2015609157 @default.
• W2005768504 cites W2032501682 @default.
• W2005768504 cites W2040051436 @default.
• W2005768504 cites W2048448495 @default.
• W2005768504 cites W2053573626 @default.
• W2005768504 cites W2055878845 @default.
• W2005768504 cites W2064249573 @default.
• W2005768504 cites W2068833343 @default.
• W2005768504 cites W2079318223 @default.
• W2005768504 cites W2081523571 @default.
• W2005768504 cites W2084496071 @default.
• W2005768504 cites W2093915140 @default.
• W2005768504 cites W2094551801 @default.
• W2005768504 cites W2094633801 @default.
• W2005768504 cites W2095448971 @default.
• W2005768504 cites W2098171296 @default.
• W2005768504 cites W2102248390 @default.
• W2005768504 cites W2106777711 @default.
• W2005768504 cites W2110869035 @default.
• W2005768504 cites W2114495250 @default.
• W2005768504 cites W2127641014 @default.
• W2005768504 cites W2136502410 @default.
• W2005768504 cites W2145220901 @default.
• W2005768504 cites W2146203649 @default.
• W2005768504 cites W2292340114 @default.
• W2005768504 cites W231114871 @default.
• W2005768504 cites W2336801634 @default.
• W2005768504 cites W2346028181 @default.
• W2005768504 cites W4238090007 @default.
• W2005768504 cites W93783673 @default.
• W2005768504 doi "https://doi.org/10.1046/j.1365-2222.2001.01123.x" @default.
• W2005768504 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11422127" @default.
• W2005768504 hasPublicationYear "2001" @default.
• W2005768504 type Work @default.
• W2005768504 sameAs 2005768504 @default.
• W2005768504 citedByCount "7" @default.
• W2005768504 countsByYear W20057685042012 @default.
• W2005768504 countsByYear W20057685042013 @default.
• W2005768504 crossrefType "journal-article" @default.
• W2005768504 hasAuthorship W2005768504A5038000493 @default.
• W2005768504 hasAuthorship W2005768504A5069101548 @default.
• W2005768504 hasConcept C159654299 @default.
• W2005768504 hasConcept C16005928 @default.
• W2005768504 hasConcept C177713679 @default.
• W2005768504 hasConcept C203014093 @default.
• W2005768504 hasConcept C2775915377 @default.
• W2005768504 hasConcept C2778674544 @default.
• W2005768504 hasConcept C2780648854 @default.
• W2005768504 hasConcept C71924100 @default.
• W2005768504 hasConceptScore W2005768504C159654299 @default.
• W2005768504 hasConceptScore W2005768504C16005928 @default.
• W2005768504 hasConceptScore W2005768504C177713679 @default.
• W2005768504 hasConceptScore W2005768504C203014093 @default.
• W2005768504 hasConceptScore W2005768504C2775915377 @default.
• W2005768504 hasConceptScore W2005768504C2778674544 @default.
• W2005768504 hasConceptScore W2005768504C2780648854 @default.
• W2005768504 hasConceptScore W2005768504C71924100 @default.
• W2005768504 hasIssue "5" @default.
• W2005768504 hasLocation W20057685041 @default.
• W2005768504 hasLocation W20057685042 @default.
• W2005768504 hasOpenAccess W2005768504 @default.
• W2005768504 hasPrimaryLocation W20057685041 @default.
• W2005768504 hasRelatedWork W1963657046 @default.
• W2005768504 hasRelatedWork W1968509366 @default.
• W2005768504 hasRelatedWork W1974212975 @default.
• W2005768504 hasRelatedWork W2068023618 @default.
• W2005768504 hasRelatedWork W2409576732 @default.
• W2005768504 hasRelatedWork W2894856861 @default.
• W2005768504 hasRelatedWork W2918673775 @default.
• W2005768504 hasRelatedWork W3204847426 @default.
• W2005768504 hasRelatedWork W98778818 @default.
• W2005768504 hasRelatedWork W2406453052 @default.
• W2005768504 hasVolume "31" @default.
• W2005768504 isParatext "false" @default.
• W2005768504 isRetracted "false" @default.
• W2005768504 magId "2005768504" @default.
• W2005768504 workType "article" @default.